Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYG24004 in Tinea Pedis
NCT07668999Phase 1Recruiting
- Sponsor
- Sinomune Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZYG24004 in tinea pedis (8 arms), sponsored by Sinomune Pharmaceutical. Primary endpoints: Incidence of serious adverse events at Day 43, Incidence of Grade 3 or higher treatment-emergent adverse events or TEAEs leading to withdrawal at Day 43 and 7 more. Started Jul 2026; status: recruiting.
02
Drugs
ZYG24004
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT07668999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668999.